Silencing intracellular LKB1 is also followed by an increase in the level of PD-L1 [77], and the loss of Stk11/Lkb1 is reported to promote resistance to anti-PD-(L)1 in KRAS mutant lung adenocarcinoma [78] (Fig. 4). This evidence concerns the gene STK11 and lung adenocarcinoma.